COMMUNIQUÉS West-GlobeNewswire

Merus to Report Full Year 2017 Financial Results and Corporate Developments on April 26, 2018
19/04/2018
Conference call scheduled for Thursday, April 26, 2018, at 8:30 a.m. ET UTRECHT, The Netherlands, April 19, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS ), a clinical-stage immuno-oncology company developing [...]
XORTX Announces PKD Foundation Collaboration
19/04/2018
CALGARY, Alberta, April 19, 2018 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE:XRX) is pleased to announce that the PKD Foundation has recognized XORTX as a leader in advancing the [...]
Summit Completes Dosing of Ezutromid in PhaseOut DMD Clinical Trial
19/04/2018
Top-line Data On-track to be Reported During Q3 2018 OXFORD, United Kingdom and CAMBRIDGE, Mass., April 19, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ: SMMT ) (AIM:SUMM) announces the completion of [...]
Emergent BioSolutions to Release First Quarter 2018 Financial Results and Conduct a Conference Call on May 3, 2018
19/04/2018
GAITHERSBURG, Md., April 19, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS ) will host a conference call on Thursday, May 3, 2018 at 5:00 pm (Eastern Time) to discuss the financial results for the first [...]
This Week in the News: A Curated Selection of the Best Media Coverage on PotNetwork Holdings, Inc.
19/04/2018
PotNetwork Holdings, Inc. featured in International Business Times, Small Cap Network, Born2Invest, Natural Way & Ultra Meds Global FT LAUDERDALE, Fla., April 19, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- [...]
Adamas Announces Final Results from the Two-Year Phase 3 Open-Label Study of GOCOVRI™ in Parkinson’s Disease Patients with Dyskinesia
19/04/2018
-- Patients receiving GOCOVRI experienced long-term durability for up to two years -- -- Safety profile was consistent with previously-published controlled Phase 3 studies -- EMERYVILLE, Calif., April 19, 2018 (GLOBE [...]
Oasmia has completed a private placement of new convertible instruments in a total amount of SEK 26,000,000
19/04/2018
Uppsala, Sweden April 19, 2018 – Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) hereby announces that the Company has completed a private placement of a convertible loan in the amount of SEK 26,000,000 with [...]
Motif Bio Announces New Iclaprim Data being Presented at ECCMID 2018
19/04/2018
NEW YORK, April 19, 2018 (GLOBE NEWSWIRE) -- Positive efficacy and safety highlights from Phase 3 REVIVE-2 trial in ABSSSI Potential to avoid costs related to vancomycin-associated acute kidney injury in ABSSSI Data [...]
Herantis Pharma awarded Innovation prize of the Chemical Industry Federation of Finland
19/04/2018
Herantis Pharma awarded Innovation prize of the Chemical Industry Federation of Finland Herantis Pharma Plc Press release 19 Apr 2018 at 8:30 am The Innovation prize 2018 of Finland's Chemical Industry Federation was [...]
Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer
19/04/2018
Basel, April 19, 2018 - Novartis announced today the appointment of John Tsai, M.D. as Head of Global Drug Development (GDD) and Chief Medical Officer. Dr. Tsai will join Novartis on May 1, 2018, and will be based in [...]
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
19/04/2018
REGULATED INFORMATION GHENT, Belgium, 19 April 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]
Novartis delivered a strong first quarter and acted to become a more focused medicines company
19/04/2018
Net sales grew 4% (cc[1], +10% USD) mainly driven by: Entresto grew to USD 200 million, +126% (cc) driven by increased uptake world wide Cosentyx was USD 580 million, +35% (cc) with strong growth in all indications and [...]
Novartis a réalisé une bonne performance au premier trimestre et agi pour devenir une entreprise plus centrée sur les médicaments
19/04/2018
Hausse du chiffre d'affaires net de 4% (tcc[1], +10% USD), stimulée principalement par: Entresto , qui a atteint USD 200 millions, soit +126% (tcc), soutenu par son adoption croissante dans le monde entier Cosentyx qui [...]
Curetis Launches CE-IVD Marked Unyvero Urinary Tract Infection (UTI) Cartridge at ECCMID 2018
19/04/2018
Curetis Launches CE-IVD Marked Unyvero Urinary Tract Infection (UTI) Cartridge at ECCMID 2018 UTI panel covers 103 diagnostic targets 443-patient multi-center study demonstrates overall weighted average sensitivity of [...]
Idorsia announces financial results for the first quarter 2018
19/04/2018
Allschwil, Switzerland - 19 April 2018 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2018. Jean-Paul Clozel, MD and Chief Executive Officer, commented : "We are advancing four [...]
Bone Therapeutics Notice of Full Year 2017 Results
19/04/2018
Press release Bone Therapeutics Notice of Full Year 2017 Results Results to be announced on Wednesday 25 April 2018 Gosselies, Belgium, 19 April 2018, 7am CEST - BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), [...]
Bone Therapeutics publiera ses résultats financiers 2017, le mercredi 25 avril 2018
19/04/2018
Communiqué de presse Bone Therapeutics publiera ses résultats financiers 2017, le mercredi 25 avril 2018 Gosselies, Belgique, le 19 avril 2018, 7h00 CEST - BONE THERAPEUTICS (code Euronext Bruxelles et Paris : BOTHE, [...]
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
19/04/2018
REGULATED INFORMATION GHENT, Belgium, 19 April 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]
Aeglea BioTherapeutics Prices Public Offering of Common Stock
19/04/2018
AUSTIN, Texas, April 18, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (Nasdaq: AGLE ) a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with [...]

Pages